Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Income from Continuing Operations (2022 - 2025)

BioXcel Therapeutics has reported Income from Continuing Operations over the past 4 years, most recently at 13888000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 13888000.0 for Q4 2025, up 3.57% from a year ago — trailing twelve months through Dec 2025 was 65167000.0 (up 18.56% YoY), and the annual figure for FY2025 was 64727000.0, up 18.86%.
  • Income from Continuing Operations for Q4 2025 was 13888000.0 at BioXcel Therapeutics, up from 18365000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for BTAI hit a ceiling of 13463000.0 in Q1 2025 and a floor of 54052000.0 in Q2 2023.
  • Median Income from Continuing Operations over the past 4 years was 23907000.0 (2023), compared with a mean of 30462625.0.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 65.92% in 2023 and later soared 63.42% in 2024.
  • BioXcel Therapeutics' Income from Continuing Operations stood at 53468000.0 in 2022, then soared by 60.74% to 20991000.0 in 2023, then soared by 31.39% to 14402000.0 in 2024, then rose by 3.57% to 13888000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 13888000.0 (Q4 2025), 18365000.0 (Q3 2025), and 19451000.0 (Q2 2025) per Business Quant data.